Chase Investment Counsel’s Indivior Pharmaceuticals INDV Stock Holding History

Chase Investment Counsel’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.32M	Buy	+129,734	New	+$4.71M	1.12%	28

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chase Investment Counsel's INDV Position: Q2 2026 in Review

Chase Investment Counsel opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 129,734 shares worth $5.32M. The stake represents 1.12% of the portfolio and ranks #28 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Chase Investment Counsel held 129,734 shares of Indivior Pharmaceuticals worth $5.32M as of Q2 2026.
Indivior Pharmaceuticals was a new Chase Investment Counsel position in Q2 2026.
Indivior Pharmaceuticals made up 1.12% of Chase Investment Counsel's portfolio in Q2 2026, its #28 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Chase Investment Counsel's 13F filing for Q2 2026, filed 6 Aug 2026.